Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients – results from the prospective 12-months phase of Lanro-Study

Abstract

Aim of the studyTo assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland.Material and methodsA multicentre, non-interventional, observational study on resource utilization in Polish acromegalic patients treated with ATG120 at 4 weeks or extended (> 4 weeks) dosing interval. The study recruited adult acromegalic patients treated medically for ≥ 1 year including at least 3 injections of ATG120. Data on dosing interval, aspects of administration, and resource utilization were collected prospectively during 12 months. Costs were calculated in PLN from the public health-care payer perspective for the year 2013.Results139 patients were included in the analysis. Changes in dosing regimen were reported in 14 (9.4%) patients. Combined treatment was used in 11 (8%) patients. Seventy patients (50%) received ATG120 at an extended dosing interval; the mean number of days between injections was 35.56 (SD 8.4). ATG120 was predominantly administered in an out-patient setting (77%), by health-care professionals (94%). Mean time needed for preparation and administration was 4.33 and 1.58 min, respectively, mean product wastage – 0.13 mg. Patients were predominantly treated in an out-patient setting with 7.06 physician visits/patient/year. The most common control examinations were magnetic resonance imaging of brain and brain stem (1.36/patient/year), ultrasound of the neck (1.35/patient/year), GH (1.69/patient/year), glycaemia (1.12/patient/year), IGF-1 (0.84/patient/year), pituitary-thyroid axis hormone levels assessment (TSH-0.58/patient/year, T4-0.78/patient/year). There were 0.43 hospitalizations/patient/year. For direct medical costs estimated at PLN 50 692/patient/year the main item was the costs of ATG120 (PLN 4103.87/patient/month; 97%). The mean medical cost, excluding pharmacotherapy, was PLN 1445/patient/year (out-patient care – 49%, hospitalization – 23%, diagnostics/laboratory tests – 28%).ConclusionsThese results represent the current use of ATG120 in the population of Polish acromegalic patients in a realistic clinical setting. Findings that 50% of patients could be treated with dose intervals of longer than 28 days support the potential of ATG120 to reduce the treatment burden.

Dawkowanie i koszt lanreotydu Autogel 120 mg stosowanego w leczeniu akromegalii w Polsce — wyniki 2-letniego badania Lanro-Study

“…ATG120 was predominantly administered in an outpatient setting by a health care professional. The results obtained during two years were consistent with those described in interim analysis with follow-up of one year [6]. This analysis revealed that 50% of patients received ATG120 at an extended dosing interval, and the mean number of days between injections was 35.6 (SD 8.4).…”

“…This analysis revealed that 50% of patients received ATG120 at an extended dosing interval, and the mean number of days between injections was 35.6 (SD 8.4). ATG120 was predominantly administered in an outpatient setting (77%) by a health care professional (94%) [6]. When interpreting the results of this study it is important to note the three following assets: First, the results have been obtained from a prospective study.…”

“…So far, limited data have been published concerning dosing patterns and the cost of somatostatin analogues used for treatment of acromegalic patients in routine clinical practice [5,6]. Findings that in a one-year time horizon approximately 50% of patients could be treated with dose intervals of longer than 28 days document the potential of ATG 120 to reduce treatment burden [5,6].…”

“…Findings that in a one-year time horizon approximately 50% of patients could be treated with dose intervals of longer than 28 days document the potential of ATG 120 to reduce treatment burden [5,6].…”

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

“…In addition, a growing body of evidence, including an expert consensus statement [4], suggests that extended dosing intervals (EDIs) with lanreotide autogel 120 mg of up to 8 weeks (versus the standard 4-week dosing interval) may be equally effective in patients who have achieved good biochemical control with long-acting SSAs [8][9][10]. The most relevant benefits of extending the treatment interval are fewer injections, lower costs, more convenient treatment; in addition, EDIs and/or dose reductions have both been shown to reduce the risk of treatment-related side-effects [3,4,9,11]. Numerous open-label trials have shown that lanreotide autogel 120 mg administered at dosing intervals >4 weeks provides comparable biochemical control to that achieved with standard dosing intervals [4,[9][10][11][12][13][14].…”